|本期目录/Table of Contents|

[1]张 瑜,李 娟,万 强,等.131I标记多肽K237的最佳条件及标记肽的体外生物活性[J].宁夏医科大学学报,2013,(03):252-255.
 ZHANG Yu,LI Juan,WAN Qiang,et al.The Optimum Conditions for Labeled Polypeptide K237 with 131I and the Bioactivity of 131I-K237 in Vitro[J].Ningxia Medical University,2013,(03):252-255.
点击复制

131I标记多肽K237的最佳条件及标记肽的体外生物活性(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2013年03期
页码:
252-255
栏目:
论著
出版日期:
2013-03-20

文章信息/Info

Title:
The Optimum Conditions for Labeled Polypeptide K237 with 131I and the Bioactivity of 131I-K237 in Vitro
作者:
张 瑜1李 娟2 万 强3 张 伟3
1.宁夏医科大学,银川 750004; 2.宁夏医科大学总医院核医学科,银川 750004; 3.泸州医学院附属医院核医学科,泸州 646000
Author(s):
ZHANG Yu1 LI Juan2 WAN Qiang3 ZHANG Wei3
1.Ningxia Medical University,Yinchuan 750004; 2.The General Hospital of Ningxia Medical University, Department of Nuclear Medicine,Yinchuan 750004; 3.The Affiliated Hospital of LuZhou Medical College, Department of Nuclear Medicine,Luzhou 646000
关键词:
多肽K237 131I标记 Iodogen 高效液相 SephadexG25
Keywords:
polypeptideK237 131I mark Iodogen HPLC SephadexG25
分类号:
R817
DOI:
-
文献标志码:
A
摘要:
目的 探索131I标记多肽K237,获得放射化学纯度高于95%的131I-K237的最佳条件,研究标记产物的体外稳定性及生物学活性。方法 应用Iodogen法对K237进行131I标记,采用正交实验筛选最佳标记条件。用高效液相色谱仪(HPLC)联合薄层层析法(TLC)测定标记率及放射化学纯度,SephadexG25层析柱分离纯化131I-K237。将分离纯化的131I-K237(放射化学纯度大于95%)分别放置于室温及37℃水浴箱,于不同时间测定其放射化学纯度以观察其稳定性。应用cck-8法进行人脐静脉内皮细胞(HUVEC)增殖抑制实验,分别计算K237及131I-K237对HUVEC的抑制率,判定131I-K237的生物活性。结果 最佳标记条件中,K237 100 μg与Iodogen 50 μg,在37℃条件下反应时间40 min,标记率可达70%以上。稳定性实验结果表明,131I-K237在体外放置24 h后,其放射化学纯度>90%。131I-K237和K237对HUVEC细胞增殖的抑制率差异无统计学意义(P>0.05),说明K237被131I标记后,其生物学活性未改变。结论 Iodogen法131I标记多肽K237简单高效,标记产物的生物活性得到保留,未受明显破坏。
Abstract:
Objective To explor the optimum conditions of the radiolabeling of the peptide K237 with the radionuclide 131I and to investigate the stability and bioactivity of 131I-K237 in vitro. Methods Iodogen method was used to label the peptide K237 and the orthogonal experiment was used to screen the optimum conditions. The labeling rate and radiochemical purity of the 131I-K237 was measured by the HPLC and TLC. 131I-K237 was isolated and purified by the SephadexG25. Its stability was studied by determining the radiochemical of the 131I-K237 at special time. The cell proliferation assays and cell affinity assays of the HUVEC were studied by the cck-8 method. The inhibition of the HUVEC by the K237 and the 131I-K237 were measured to investigate the biological activity of 131I-K237. Results The optimum conditions of the radiolabeling of the peptide K237 with 131I were K237 100μg, iodogen 50μg, reaction temperature 37℃ and reaction time 40min.The labeling rate was higher than 70%. The radiochemical purity of 131I-K237 was still higher than 90% when stayed in vitro 24 hours. There were no significant differences between the inhibition of the HUVEC treated with K237 and the 131I-K237. The biological activity of K237 was not changed by labeling. Conclusion K237 can be labeled readily with 131I by the Iodogen method and its biological activity is not changed.

参考文献/References:

[1] Roskoski RJ.Vascular endothelial growth factor(VEGF)signaling in tumor progression [J].Curr Pharm Des,2007,13(1):17-31.
[2] Dai J,Rabie AB.VEGF:an essential mediator of both an-giogenesis and endochondral ossification[J].J Dent Res,2007,86(10):937-950.
[3] Lei Hetian,An Ping.A novel pep tide isolated from a phage disp lay library inhibits tumor growth and metastasis by blockingthe binding of vascular endothelial growth factor to its kinase domain receptor[J].J Biol Chem,2002,227(45):43137-43142.
[4] Van den Bossche B,Van dewiele C.Recepto rimaging in oneology by means of nuclear medicine:current status[J].Clin Oncol,2004,22(17):3593-3607.
[5] Kreng EP,Kwekkeboom DJ,valkema R,et al.Peptide receptor dlonuelide therapy.[J].Ann NYA cad Sci,2004,1014:234-245.
[6] Yang DJ,Kim KD,Seheehter NR,et al.Assessmentof Antlangiogenic Effect Using 99mTc-EC一Endostatin.cancer Biother[J].Radiophann,2002,17(2):233-245.
[7] Lee KH,Song SH,Paik JY,et al.Specific endothelial binding and Tumor uptake of radiolabeleda ngiostain.Eur[J].NuelMed MolImaging,2003,30(7):1032-1037.
[8] 王火强,夏俊勇,赵龙,等.99mTc-K237 的制备及其在小鼠体内分布和显像[J].中国医学影像技术,2009,25(9):1545-1545.
[9] 徐清华,粟波,赵印敏,等.(131)Ⅰ标记血管靶向分子在肿瘤显像中的应用[J].肿瘤防治研究,2007,25(11):860-863.

相似文献/References:

[1]齐喜红,高 萌,丁 锐.HPLC法测定石龙清血颗粒中天麻素的含量[J].宁夏医科大学学报,2018,(08):988.[doi:10.16050/j.cnki.issn1674-6309.2018.08.033]
[2]王秀芬,陈海燕,冷晓红.苦豆草植物HPLC指纹图谱的建立[J].宁夏医科大学学报,2016,(07):763.[doi:10.16050/j.cnki.issn1674-6309.2016.07.009]
 WANG Xiufen,CHEN Haiyan,LENG Xiaohong.HPLC Fingerprint of Sophora alopecuroides L.[J].Ningxia Medical University,2016,(03):763.[doi:10.16050/j.cnki.issn1674-6309.2016.07.009]
[3]杜伟,彭力,王青欢,等.高效液相色谱法测定人血浆中依托泊苷浓度[J].宁夏医科大学学报,2015,(07):851.[doi:10.16050/j.cnki.issn1674-6309.2015.07.041 ]
[4]王秀芬,张福宝.五淋化石胶囊中绿原酸HPLC检测方法的建立及其评价[J].宁夏医科大学学报,2015,(08):983.[doi:10.16050/j.cnki.issn1674-6309.2015.08.037]
[5]张惠勇,马荣,陈振,等.载异烟肼、利福平白蛋白纳米粒中利福平在兔脊柱中的药代动力学研究[J].宁夏医科大学学报,2015,(04):375.[doi:10.16050/j.cnki.issn1674-6309.2015.04.005]
 ZHANG Huiyong,MA Rong,CHEN Zhen,et al.[J].Ningxia Medical University,2015,(03):375.[doi:10.16050/j.cnki.issn1674-6309.2015.04.005]
[6]魏世杰,文友民,杨小英,等.九种国产盐酸二甲双胍片溶出度的比较[J].宁夏医科大学学报,2008,(04):537.
[7]许大庆,魏世杰,贺罡.头孢噻肟钠与奥硝唑氯化钠注射液配伍的稳定性研究[J].宁夏医科大学学报,2008,(01):115.
[8]OPA在线柱前衍生化HPLC-FLD法测定人血浆中硫酸阿米卡星的浓度.OPA在线柱前衍生化HPLC-FLD法测定人血浆中硫酸阿米卡星的浓度[J].宁夏医科大学学报,2009,(05):694.
[9]郭 珺,李 娟,张 瑜.131I标记多肽K237用于前列腺癌荷瘤裸鼠显像的实验研究[J].宁夏医科大学学报,2013,(07):752.
 GUO Jun,LI Juan,ZHANG Yu.Experimental Study on the Peptides K237 Radiolabeled with Iodine-131 for Targeting Imaging in Nude Mice Bearing Human Prostate Cancer[J].Ningxia Medical University,2013,(03):752.

备注/Memo

备注/Memo:
收稿日期:2012-09-02 基金项目:宁夏自然科学基金项目(NZ10140) 作者简介:张瑜(1982-),男,在读硕士研究生,从事影像医学与核医学专业。 通信作者:李娟。E-mail:Lijuan6161@yahoo.com.cn
更新日期/Last Update: 2013-03-20